Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20644803 | 0.94 | FAAH (0.43) | MEN1KMT2AFAAHMAPK1ASAH2 | |
| SCHEMBL20644804 | 0.93 | FAAH (0.46) | MEN1KMT2AFAAHMAPK1ASAH2 | |
| SCHEMBL17231647 | 0.93 | FAAH (0.46) | MEN1KMT2AFAAHMAPK1ASAH2 | |
| SCHEMBL18541216 | 0.84 | MEN1 (0.57) | MEN1KMT2AFAAHMAPK1ALDH1A1 | |
| SCHEMBL23521094 | 0.79 | FAAH (0.43) | MEN1KMT2AFAAHMAPK1ASAH2 | |
| SCHEMBL23913185 | 0.79 | SMN1; SMN2 (0.34) | ALDH1A1SMN1; SMN2GAAHPGDNPSR1 | |
| SCHEMBL8298120 | 0.78 | FAAH (0.59) | MEN1KMT2AFAAHMAPK1ASAH2 | |
| SCHEMBL9158547 | 0.77 | FAAH (0.63) | MEN1KMT2AFAAHMAPK1ASAH2 | |
| SCHEMBL9738234 | 0.77 | FAAH (0.63) | MEN1KMT2AFAAHMAPK1ASAH2 | |
| SCHEMBL9150544 | 0.77 | FAAH (0.63) | MEN1KMT2AFAAHMAPK1ASAH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10716801-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190183913-A1 | Silanol Based Therapeutic Payloads | BLINKBIO INC (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183913-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | MEN1 2446/4885KMT2A 2014/4885FAAH 3066/4885 |
| US-10716801-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | MEN1 2446/4885KMT2A 2014/4885FAAH 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.